Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcturus Therapeutics Holdings Inc ARCT

Healthcare Biotechnology
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid... see more

Recent & Breaking News (NDAQ:ARCT)

Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023

Business Wire July 24, 2023

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency

Business Wire June 1, 2023

Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress

Business Wire May 9, 2023

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023

Business Wire April 26, 2023

Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress

Business Wire March 28, 2023

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023

Business Wire March 7, 2023

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Business Wire February 6, 2023

Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis

Business Wire January 31, 2023

Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Business Wire December 19, 2022

Arcturus Appoints John Markels, Ph.D. to its Board of Directors

Business Wire December 13, 2022

CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics

PR Newswire December 12, 2022

Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress

Business Wire November 9, 2022

Arcturus Therapeutics to Present at the Following Investor Conferences in November

Business Wire November 7, 2022

Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines

Business Wire November 1, 2022

CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology

PR Newswire November 1, 2022

Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022

Business Wire October 26, 2022

Arcturus Therapeutics to Attend the Following Investor Conferences

Business Wire September 27, 2022

Arcturus Therapeutics to Attend the Following Investor Conferences

Business Wire September 1, 2022

Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response

Business Wire August 31, 2022

Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine

Business Wire August 18, 2022